Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1970 5
1971 2
1972 2
1976 1
1980 1
1981 2
1983 3
1984 6
1985 11
1986 7
1987 5
1988 5
1989 9
1990 8
1991 7
1992 7
1993 11
1994 9
1995 2
1996 7
1997 5
1998 11
1999 9
2000 19
2001 28
2002 26
2003 20
2004 25
2005 32
2006 35
2007 46
2008 33
2009 36
2010 30
2011 36
2012 21
2013 38
2014 60
2015 76
2016 85
2017 82
2018 66
2019 81
2020 63
2021 83
2022 50
2023 66
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

1,143 results

Results by year

Filters applied: . Clear all
Page 1
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Sweeney CJ, et al. N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5. N Engl J Med. 2015. PMID: 26244877 Free PMC article. Clinical Trial.
Next generation radiotheranostics promoting precision medicine.
Pomykala KL, Hadaschik BA, Sartor O, Gillessen S, Sweeney CJ, Maughan T, Hofman MS, Herrmann K. Pomykala KL, et al. Among authors: sweeney cj. Ann Oncol. 2023 Jun;34(6):507-519. doi: 10.1016/j.annonc.2023.03.001. Epub 2023 Mar 15. Ann Oncol. 2023. PMID: 36924989 Review.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Kyriakopoulos CE, et al. Among authors: sweeney cj. J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31. J Clin Oncol. 2018. PMID: 29384722 Free PMC article. Clinical Trial.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. Among authors: sweeney cj. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis.
Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. Riaz IB, et al. Among authors: sweeney c. JAMA Oncol. 2023 May 1;9(5):635-645. doi: 10.1001/jamaoncol.2022.7762. JAMA Oncol. 2023. PMID: 36862387 Free PMC article.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Body language.
Sweeney CY. Sweeney CY. JAAPA. 2022 Mar 1;35(3):66. doi: 10.1097/01.JAA.0000819528.46724.ce. JAAPA. 2022. PMID: 35192558 No abstract available.
Targeting a ceramide double bond improves insulin resistance and hepatic steatosis.
Chaurasia B, Tippetts TS, Mayoral Monibas R, Liu J, Li Y, Wang L, Wilkerson JL, Sweeney CR, Pereira RF, Sumida DH, Maschek JA, Cox JE, Kaddai V, Lancaster GI, Siddique MM, Poss A, Pearson M, Satapati S, Zhou H, McLaren DG, Previs SF, Chen Y, Qian Y, Petrov A, Wu M, Shen X, Yao J, Nunes CN, Howard AD, Wang L, Erion MD, Rutter J, Holland WL, Kelley DE, Summers SA. Chaurasia B, et al. Among authors: sweeney cr. Science. 2019 Jul 26;365(6451):386-392. doi: 10.1126/science.aav3722. Epub 2019 Jul 4. Science. 2019. PMID: 31273070 Free PMC article.
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Ledwidge M, Dodd JD, Ryan F, Sweeney C, McDonald K, Fox R, Shorten E, Zhou S, Watson C, Gallagher J, McVeigh N, Murphy DJ, McDonald K. Ledwidge M, et al. Among authors: sweeney c. JAMA Cardiol. 2023 Apr 1;8(4):366-375. doi: 10.1001/jamacardio.2023.0065. JAMA Cardiol. 2023. PMID: 36884247 Free PMC article. Clinical Trial.
1,143 results